A substantial number of patients with asthma require systemic corticosteroids to control symptoms 148 and/or suffer from poor control and frequent severe exacerbations despite currently available 149 treatment (1, 2) . Although recently-developed biologic compounds targeting cytokines of the Type 2 150 pathways show promise (3, 4) , identification of new treatment targets and the selection of patients 151 best suited to respond to individual biologics is still hampered by a poor understanding of the 152 physiological, pathological, and molecular heterogeneity of severe asthma (5, 6) . 153 154 Severe asthma is a collection of disease entities with varying pathophysiological characteristics (7) 155 that result in symptoms of cough, wheeze and breathlessness, with frequent exacerbations. To 156 address the problem of phenotypic difference and heterogeneity, the Unbiased Biomarkers for the 157 Prediction of Respiratory Disease Outcomes (U-BIOPRED) project was set up in 2009 as a public-158 private partnership within the framework of the Innovative Medicines Initiative (IMI), engaging 159 academia, the pharmaceutical industry and patient groups. The aim of U-BIOPRED is to identify 160 multi-dimensional phenotypes of severe asthma and new treatment targets using a combination of 161 state of the art 'omics' (transcriptomic, proteomic, lipidomic and metabolomic) technologies 162 applying a systems biology approach (8) thereby driving unbiased discovery in both adult and 163 paediatric severe asthma (9) . This novel approach is designed to make drug development more 164 effective and efficient. 165 166 We present the baseline characteristics of the adult participants with severe asthma who form the 167 majority of the U-BIOPRED cohort and compare these participants with those suffering from with 168 mild-to-moderate disease, in terms of their clinical, symptomatic, functional and biomarker features. 169
In a parallel paper the characteristics of the paediatric cohort are reported. These first publications 170 of U-BIOPRED will serve as the reference documents for all subsequent publications using the 'omics 171 technologies which are at the core of this programme. 172 173 Methods 174
Participants 175
This was a multi-centre prospective cohort study recruiting from 16 clinical centres in 11 European 176 countries. Details of the participating centres, assessments, and standard operating procedures are 177 available in the online supplement. Prior to enrolment, participants with severe asthma were 178 required to have been under follow-up by a respiratory physician for at least six months during 179 which time assessments had been undertaken to optimise asthma control and assess medication 180 adherence (2) . The study was approved by the ethics committee for each participating clinical 181 institution, and adhered to the standards set by International Conference on Harmonisation and 182 Good Clinical Practice. It is registered on ClinicalTrials.gov, (Identifier: NCT01982162). All participants 183 gave written and signed informed consent. 184
185

Adult Groups 186
The definition of severe asthma used in this study was agreed at a U-BIOPRED consensus meeting 187 (2) . Participants with asthma had either airflow reversibility (increase in FEV1 >12% predicted or 188 200ml following inhalation of 400µg salbutamol), airway hyper-responsiveness (methacholine PC20 < 189 8mg/ml, or diurnal PEF amplitude % mean >8%), or a decrease in FEV1 of 12% predicted or 200ml 190 within 4 weeks after tapering maintenance treatment. Four groups were recruited: 191 192 A) Severe non-smoking asthma (SAn): 193
Participants in this group were non-smokers for at least the past 12 months, with a less than five 194
pack-year smoking history, with asthma and uncontrolled symptoms defined according to GINA 195 guidelines (10) Participants in this group were non-smokers for at least the past 12 months, with a less than five 204
pack-year smoking history and had controlled or partially controlled asthma symptoms, as defined 205 by the Global Initiative for Asthma (GINA), whilst receiving a dose of less than 500µg fluticasone 206 propionate/day or equivalent. 207
D) Healthy non-smoking controls (HC): 209
These participants had no history of asthma or wheeze, had no other chronic respiratory disease, 210
were non-smokers for at least the past 12 months with a smoking history of ≤ 5 pack years and their 211 pre-bronchodilator FEV1 was ≥ 80% predicted. 212
213
Protocol and assessments 214
Participants attended a screening visit to assess eligibility for the study (Fig 1) . They underwent a 215 baseline visit (up to 28 days later) and were invited to attend for an optional bronchoscopy, high 216 resolution lung computed tomography and telemonitoring sessions. Spirometry, haematological 217 profiles, and fraction of exhaled nitric oxide level (FeNO) at 50ml/sec were performed. Induced 218 sputum was obtained (11) and differential sputum eosinophil and neutrophil counts measured 219 following a standardised operating procedure. Sputum supernatants and cell pellets were collected. 220 The following were administered at baseline: 243 1.
The Asthma Control Questionnaire (ACQ5) (13) to assess current asthma control. 244
2.
The Asthma Quality of Life Questionnaire (AQLQ) (14) to assess quality of life and 245 psychological morbidity. 246
3.
The Hospital Anxiety and Depression Scale (HADS) (15) . 247
4.
Sino-Nasal Outcomes Test (SNOT20) (16) to measure upper airway symptoms. 248
5.
The Epworth Sleepiness Scale (ESS) (17) to measure sleep and daytime drowsiness. 249 6.
The Medicines Adherence Response Scale (MARS) (18) The MARS questionnaire scores for adherence to treatment recorded by the three asthma groups 313 were in the range of 21 to 22, with the severe asthma groups recording higher scores (p<0.005) 314
indicating better adherence. The AQLQ score was correlated to several variables, including FEV1 (95% 315 CI 0.5_0.7, p<0.001), FEV1/FVC (95% CI 1.14_2.8, p<0.001), exacerbations in the previous year (95% 316 CI -0.8_-0.2, p<0.001), BMI (95% CI -000.6_-0.002, p<0.001) and pack years smoked (95% CI -0.003_-317 0.001, p<0.001) (Figure 3) . 318 319 Atopy and co-morbidities (Table iv ) 320
There was a high incidence of atopy in the 4 groups, at 70% in the asthma groups and 46% in the HC 321 group. The incidence of allergic rhinitis, hay fever and non-allergic rhinitis were highest in the 322 asthma groups. The HC group were much less allergic with only a third reporting hay fever and only a 323 The presence of nasal polyps was associated with severe asthma, regardless of smoking status fold increased incidence in SAn and SAs/ex groups versus MMA group, p < 0.001) (Table iv) . No such 333 association was seen with allergic or non-allergic rhinitis, hay fever or reported eczema. Gastro-334 oesophageal reflux disease was more common in severe asthma (46% SAn, 63% SAs/ex) than in 335 MMA (21%) and HC (11%), with a greater incidence reported in the SAs/ex group versus the SAns 336 group (p=0.004). 337 338 Blood and sputum biomarkers ( 4) . 355
There were no significant differences in differential sputum neutrophil counts between the two 356 severe asthma groups, which when combined were significantly higher compared to the MMA group 357 (Table v) . 358
There was a significant negative association between log sputum eosinophils (Absolute or %) and 359 FEV1 (% predicted or actual value) when all cohorts were considered and an adjustment for age, sex 360 and smoking was applied. There were significant negative associations between log blood 361 eosinophils (%) and FEV1/FVC ratio (p=0.002) and between blood neutrophils (%) and actual FEV1 362 (p=0.002) and FEV1/FVC ratio (p=0.026). 363
Exhaled Nitric Oxide (FeNO) (Table v) 364
FeNO levels in all asthma groups were higher than those in the HC group, but the FeNO levels in the 365 severe asthma groups were not different from the levels in the MMA group. The presence of nasal 366 polyps was associated with a higher FeNO (mean increase 2.1ppb, 95% CI 1.5_2.9, p<0.001). 367 368 Discussion 369
In this large European cohort, patients with severe asthma experienced more symptoms, more 370 exacerbations, higher levels of anxiety and depression, and a higher incidence of nasal polyps, 371 gastro-oesophageal reflux symptoms and airflow obstruction than patients with milder disease. The 372 clinical characteristics of asthma were present despite higher doses of treatment that included doses 373 of inhaled corticosteroids equal or more than 1,000µg of fluticasone (or equivalent), with 45% of the 374 combined severe asthma group receiving a daily dose of prednisolone. The characteristic features of 375 the severe asthma U-BIOPRED cohort are similar to those reported in previous cohort studies (6, 19-376 21) . While the entry criteria for severe asthma were comparable for most of these cohort studies, 377 the ENFUMOSA study required a lower threshold with an ICS dose of ≥ 1,200µg of budesonide or 378 beclomethasone with at least one exacerbation in the past year. Of these 5 cohorts, the current U-379 BIOPRED severe asthma cohort appears to be the most severe with a higher reported exacerbation 380 rate of 2.5 per year, a reduced mean FEV1 of 67.5% of predicted and a higher proportion of patients 381 on oral corticosteroid therapy taking a mean dose of 14 mg/day. 382
One of the novel features of the U-BIOPRED cohort is the inclusion of a smoking and ex-smoking 384 severe asthma group. Patients with asthma who smoke have been reported to have poorer disease 385 control and a reduced therapeutic response to ICS (22) , possibly through the induction of 386 corticosteroid insensitivity (23, 24) . However our analyses of the non-smoking and the smoking/ex 387 smoking severe asthma groups identified few differences in demographics, airway physiology, 388 inflammatory markers and asthma symptoms between these groups. In both groups, a similar 389 percentage received oral corticosteroid therapy; they also had similar degrees of airflow 390 obstruction. The slightly lower level of FeNO in the smoking/ex smoking group might be explained 391
by an effect of current smoking (26) . One notable difference is that asthma onset occurred on 392 average 18 years later in the smokers and ex-smokers than in the non-smokers, and yet the degree 393 of airflow obstruction measured was similar. One interpretation is that there may be a more rapid 394 rate of loss of lung function in the patients with asthma who smoke. The significant correlation 395 between AQLQ scores and the number of pack-years of smoking exposure would also support a 396 contribution of cigarette smoke to impaired quality of life in this group. We also split the 397 demographic data of the groups by smoking status rather than severity (see Table S5 ) in the online 398 supplement. This revealed that current smokers had a lower BMI compared with ex and never 399 smokers. 400
401
In agreement with the SARP study (20) , patients with severe asthma (especially smokers) were less 402 frequently atopic than those with mild/moderate disease. There was also a clear association of both 403 nasal polyps and gastro-oesophageal reflux disease with disease severity, with approximately one-404 third and one half reporting polyps and reflux respectively, a finding that is in keeping with previous 405 reports (5) . Nasal polyps are commonly found in severe asthma, and are associated with a 406 particularly severe phenotype. There is evidence that treating nasal polyps with anti-IgE therapy 407 results in better asthma outcomes (25) , however whether this is due to an effect on the underlying 408 asthma or the polyps is unknown. The link with higher FeNO levels is in keeping with work showing 409 that nasal polypectomy leads to a fall in FeNO (26) . 410
411
Our findings are also similar to other studies published from severe asthma registries. In agreement 412 with both the British Thoracic Society's (27) and Belgium's (28) severe asthma registries our patients 413 are predominantly female, with a high BMI and evidence of fixed airflow obstruction. Moreover 414 there are similarly high levels of reflux, nasal polyps and exacerbations despite greater levels of 415 medication. 416
We found a greater degree of sputum eosinophilia in the two severe asthma groups compared to 418 the mild-moderate asthma group. Up to 60% of patients in the two severe asthma groups had a 419 differential sputum eosinophil of >1.9% (the established upper limit of normal for differential 420 sputum eosinophil counts (29) ). This percentage is similar to previous reports in severe asthma (21) . 421
The level of sputum eosinophilia observed in the mild/moderate asthma group are also similar to 422 those reported previously (30) . 423
424
The higher blood neutrophil count in participants with severe asthma may represent the effect of 425 systemic corticosteroids which can increase blood neutrophil numbers. Sputum neutrophil counts 426 were similar in the three asthma groups and were significantly higher than the in healthy control 427 group. This similarly could represent the effect of corticosteroids although severe asthma has been 428 linked to a higher level of sputum neutrophils (31, 32) . 429
430
The impact and burden on our participants' health was noticeable with measures of symptoms and 431 quality of life being far worse in severe asthma as compared to mild/moderate asthma, despite the 432 use of higher doses and more classes of asthma treatment. Levels of anxiety and depression were 433 also higher with severe asthma. There were significant relationships between quality of life 434 measures and airflow obstruction, smoking history and BMI, supporting the contribution of these 435 factors to an impairment of quality of life however the scatter of data reveals that these parameters 436 are not closely related. The number of exacerbations experienced was greater than 2.5 437 exacerbations per participant in both severe asthma groups in the preceding year. These findings 438 highlight the need for an integrative assessment of clinical and physiological disease markers but 439 additionally biological markers of disease in the assessment of severe asthma. For example, the 440 finding that bariatric surgery has an effect on measures of airway hyper-responsiveness (33) and is 441 associated with a lower all-cause mortality at 5 years particularly in younger, predominantly female 442 populations (34) may point towards the need for specific and targeted intervention in people with 443 severe asthma and obesity. 444 445 There are several limitations to our study. Firstly, there is no perfect way to assess treatment 446 adherence; however, we only approached patients managed in a specialist respiratory clinic and only 447 those who had been assessed to be adherent were eligible for the study. Furthermore MARS scores 448 were high indicating good levels of self-reported adherence. Secondly, subjective or historical data 449 were assessed by questionnaire which may be prone to recall bias. Thirdly, the success rate in 450 obtaining adequate quality sputum for analysis was in the 42-50% range and the number of 451 bronchoscopies was relatively lower in the SA and SAs/ex groups. Thirdly due to the numerous 452 formulations and inhaler devices used across Europe it was not possible to calculate the precise daily 453 equivalent ICS dose for each participant and therefore these data are not shown, however high 454 (>1000mcg FP) or low (<500mcg FP) dose was a study entry requirement for the severe and 455 moderate groups respectively. 456
457
We have been successful in recruiting a substantial cohort of patients with the most severe asthma 458 that has similar characteristics to previously-reported cohorts. This gives confidence that the U-459 BIOPRED consortium will define distinct phenotypes and endotypes of severe asthma. Matching 460 these data to the 'omics' information with future unsupervised analyses will help identify new 461 treatments for patients with severe asthma who currently have limited treatment options, and will 462 improve our understanding of this important chronic disease. 
